Applied Clinical Trials Online18h
Tecentriq Falls Short of Primary Endpoint in IMvoke010 Trial for Locally Advanced Head and Neck Cancer
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...
Sino Biopharmaceutical, One of the Largest Chinese Drugmakers, Is in the Transformation Stage
Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...
Fierce Pharma13h
FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again
Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
American Cancer Society16h
What Is Multiple Myeloma?
Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow (the soft, inner parts of certain bones where new blood cells are made). They are an important part of ...